Sources

5 Total Sources

CheckMate 77T Links Nivolumab to 66% ctDNA Clearance in Resectable NSCLC

Nature.com8d ago

CheckMate 77T Study Identifies Nivolumab Biomarkers for Resectable NSCLC Benefit

Oncodaily6d ago

CheckMate 77T study: Can ctDNA Predict Response to Perioperative Immunotherapy in NSCLC? - OncoDaily

Frontiers8d ago

Frontiers | Advancements in extensive-stage small cell lung cancer therapy: from molecular profiling to the advent of precision oncology

AJMC.com Managed Markets Network8d ago

Dr Tina Cascone Details Impact of Nivolumab Chemo-Immunotherapy on NSCLC | AJMC

National Institutes of Health (NIH) (.gov)8d ago

Integration of hierarchical clustering in hematologic biomarkers prediction for endocrine toxicity during immunotherapy in lung cancer patients - PMC